Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O14896
UPID:
IRF6_HUMAN
Alternative names:
-
Alternative UPACC:
O14896; B4DLE2; D3DT90; F5GWX8; G0ZTL0
Background:
Interferon regulatory factor 6 plays a pivotal role in epidermal development and mammary epithelial cell proliferation. It acts as a probable DNA-binding transcriptional activator, crucial for the keratinocyte proliferation-differentiation switch, ensuring proper skin formation.
Therapeutic significance:
Linked to Van der Woude syndrome 1, Popliteal pterygium syndrome, and Non-syndromic orofacial cleft 6, Interferon regulatory factor 6's understanding could pave the way for innovative treatments for these developmental disorders.